<DOC>
	<DOCNO>NCT00794417</DOCNO>
	<brief_summary>The purpose study determine whether combination aflibercept , pemetrexed cisplatin safe effective .</brief_summary>
	<brief_title>A Study Aflibercept Administered Combination With Pemetrexed Cisplatin Patients With Advanced Carcinoma</brief_title>
	<detailed_description>The study conduct two phase . In phase 1 , patient advance cancer receive different dos aflibercept combination approve dos pemetrexed cisplatin . The objective phase 1 determine safest dose combine study medication . This dose administered patient previously untreated non-small cell lung cancer phase 2 . The phase 2 portion study determine combination effective treat non-small cell lung cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Confirmation cancer biopsy ( tissue sample ) Phase 1 : patient advance metastatic disease fail conventional therapy Phase 2 : patient previously untreated NSCLC , exclude squamous cell histology cavitating lesion Age â‰¥18 year ECOG performance status 01 Adequate renal , liver bone marrow function . Negative pregnancy test ( serum urine ) females childbearing potential within 7 day initial dose aflibercept Ability comply schedule visit , treatment plan , laboratory test , study procedure Institutional Review Board ( IRB ) approve , sign date informed consent form Prior treatment study medication Untreated , symptomatic , progressive Central Nervous System cancer and/or spinal cord compression . Patients treat brain metastasis must without symptom least 3 month Surgery 4 week prior initial administration aflibercept and/or incomplete wound heal AntiVEGF therapy 4 week prior initial administration aflibercept ( phase 1 ) Chemotherapy 4 week prior initial administration aflibercept ( phase 1 ) Other investigational treatment 4 week prior initial administration aflibercept Any follow 6 month ( 24 week ) prior initial administration aflibercept : Severe cardiovascular disease event Cerebrovascular accident , transient ischemic attack , moderate severe peripheral neuropathy Erosive esophagitis gastritis , infectious inflammatory bowel disease , diverticulitis Deep vein thrombosis , pulmonary embolism , clot event Episode ( ) moderate severe , continuous bleed Breastfeeding pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>advanced cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>aflibercept</keyword>
	<keyword>chemotherapy</keyword>
</DOC>